Objective-To evaluate bone mineral density (BMD) in premenopausal patients with systemic lupus erythematosus (SLE). Methods-We measured BMD by dual energy x ray absorptiometry at lumbar vertebrae L2-4 and at the right femoral neck in 74 premenopausal white patients (mean age 30-8 years) with SLE who were receiving glucocorticoid therapy, and in a control group. Results-The mean cumulative dose of prednisone was 32*5 (SD 28) g. The mean dose at the time of absorptiometry was 13*7 (6.9) mg. BMD was significantly reduced at the spine and at the femoral neck in SLE patients when compared with the control group: L2-4 = 0*943 (0.1) g/cm2 v 1-038 (0.1) g/cm2 (p<0.001); femoral neck = 0-766 (0-09) g/cm2 v 0*864 (0.1) g/cm2 (p < 0.001). Nine patients (12-1%), but none of the control group, had a BMD less than the reference range. Conclusion-BMD in premenopausal patients with SLE was less than that in a control group and less than the reference range of values defining the presence of osteoporosis in 12X1%. We did not find a relationship between BMD and either cumulative or baseline dose of corticosteroid therapy.
neck = 0-766 (0-09) g/cm2 v 0*864 (0.1) g/cm2 (p < 0.001). Nine patients (12-1%), but none of the control group, had a BMD less than the reference range. Conclusion-BMD in premenopausal patients with SLE was less than that in a control group and less than the reference range of values defining the presence of osteoporosis in 12X1%. We did not find a relationship between BMD and either cumulative or baseline dose of corticosteroid therapy. The following data were recorded: age; age at onset of disease; duration of disease (months); cumulative dose of corticosteroids (prednisone or equivalent); dose of corticosteroids at the time that densitometry was performed (prednisone or equivalent); mean dose of corticosteroids/year; disease activity of the lupus patients, assessed with the University College Hospital/Middlesex SLE scoring system5 with a numerical score of disease activity graded from 1 to 4 (inactive to severely active disease); presence of 12 or more months of amenorrhoea (the periods of amenorrhoea not necessarily concurrent; information was sought concerning lack of bleeding during periods of at least 3 months duration); calcium intake (dietician's estimate based on review of food consumption during the eight weeks before testing).
The control group comprised 50 premenopausal women who were volunteers taking part in a screening programme of age related bone loss. They had similar age, weight, and height distribution, and regular menstrual cycles. Those with diseases or treatments that could interfere with bone metabolism were excluded.
Using ultrasensitive film in order to minimise the exposure to x rays, we obtained anteroposterior and lateral radiographs of the thoracic and lumbar spine, and anteroposterior radiographs of the hip in all the SLE patients and the control group.
In both groups of subjects, BMD in the lumbar spine and femoral neck was measured by dual energy x ray absorptiometry (DXA) using a densitometer (Hologic QDR 1000). The regions of interest analysed in the lumbar spine were L2, L3, and L4 (giving a mean value for L2-4); in the right hip, the femoral neck was chosen. Calibration of the technique against a lumbar spine phantom was performed daily and with a femoral phantom Loss of bone mineral density in premenopausal women with systemic lupus erythematosus weekly; measurement of bone mineral content was accurate to within 05% compared with the Hologic X-caliber QDR-1 Anthropomorphic Spine Phantom of known mineral content, and precision of measurement was better than 0-01 g/cm2 (coefficient of variation 1 0% at BMD 1.0 g/cm2). Patients received doses of radiation in the range 2-5 mrem (0-02-0-05 SV) per scan.
According to established criteria,6 we defined osteoporosis as present when the BMD of the lumbar spine was 2 SD less than the mean of that age group which includes subjects Our study using dual energy x ray absorptiometry has shown a high percentage of patients with low BMD in a population of 74 SLE young, premenopausal subjects: nine of our patients (12 1%) had BMD below the reference range indicating osteoporosis. We found the bone mass of the lumbar spine and femoral neck to be less in this group of SLE patients than in control subjects (p < 000 1). Fractures were not found. Our patients had a high mean cumulative dose of prednisone and a high mean dose of prednisone at the time of the study, but we did not find any relation between dose of glucocorticoid therapy and BMD in the lumbar spine or femoral neck. In addition, we did not find any correlation between BMD and disease duration or the disease activity.
Our results confirm those of Dhillon et all and Kalla et a12 in premenopausal SLE patients, which also showed no correlation between cumulative dose of prednisone and BMD, and no fractures. However, Dhillon et all found a lower frequency of osteoporosis, reporting a low BMD in one (4.5%) of 22 SLE patientsadmittedly a small sample size. In the more recent report of Kalla et al,2 25% of 46 SLE patients had BMD below the reference range.
Glucocorticoid therapy,'2 amenorrhoea,'3 hyperparathyroidism secondary to chronic renal failure,14 conscious avoidance of sunshine, immobility as a result of arthritis, and the disease itself are the most likely contributing factors in osteoporosis associated with SLE.
The pathogenesis of glucocorticoid induced osteoporosis involves inhibition of intestinal calcium absorption'5-' and increased urinary calcium excretion,'8 causing secondary hyperparathyroidism.'9 There is also inhibition of bone formation20 with enhanced bone resorption,2' and decreasing gonadal steroid '222 secretion. - Although none of our patients showed symptomatic fracture, they had lower BMD values than the normal controls. Because a low BMD predicts an increased risk for bone fractures, and because of the young age of our group (premenopausal patients), we believe that osteoporosis may become a serious problem for these patients in the future, when they reach menopause. Prophylactic strategies are needed for this group.
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